{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:19:06Z","timestamp":1777961946849,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10637-024-01471-x","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T10:01:40Z","timestamp":1728554500000},"page":"635-643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed\/refractory t(11;14) multiple myeloma patients"],"prefix":"10.1007","volume":"42","author":[{"given":"Mohamed Ali","family":"Badawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edyta","family":"Dobkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Hamed","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"1471_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","DOI":"10.3322\/caac.21708"},{"issue":"1","key":"1471_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ajh.24236","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV (2016) Myeloma today: disease definitions and treatment advances. Am J Hematol 91(1):90\u2013100. https:\/\/doi.org\/10.1002\/ajh.24236","journal-title":"Am J Hematol"},{"issue":"5","key":"1471_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516\u20132520. https:\/\/doi.org\/10.1182\/blood-2007-10-116129","journal-title":"Blood"},{"key":"1471_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.12703\/r\/11-28","volume":"11","author":"A Bobin","year":"2022","unstructured":"Bobin A, Leleu X (2022) Recent advances in the treatment of multiple myeloma: a brief review. Fac Rev 11:28. https:\/\/doi.org\/10.12703\/r\/11-28","journal-title":"Fac Rev"},{"key":"1471_CR5","doi-asserted-by":"publisher","unstructured":"Dima D, Ullah F, Mazzoni S, Williams L, Faiman B, Kurkowski A et al (2023) Management of relapsed-refractory multiple myeloma in the era of Advanced therapies: evidence-based recommendations for routine clinical practice. Cancers (Basel) 15(7). https:\/\/doi.org\/10.3390\/cancers15072160","DOI":"10.3390\/cancers15072160"},{"key":"1471_CR6","doi-asserted-by":"publisher","unstructured":"Lasica M, Anderson MA (2021) Review of Venetoclax in CLL, AML and multiple myeloma. J Pers Med 11(6). https:\/\/doi.org\/10.3390\/jpm11060463","DOI":"10.3390\/jpm11060463"},{"issue":"13","key":"1471_CR7","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","volume":"4","author":"BJ Ball","year":"2020","unstructured":"Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M et al (2020) Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv 4(13):2866\u20132870. https:\/\/doi.org\/10.1182\/bloodadvances.2020001482","journal-title":"Blood Adv"},{"issue":"17","key":"1471_CR8","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","volume":"27","author":"MS Davids","year":"2021","unstructured":"Davids MS, Roberts AW, Kenkre VP, Wierda WG, Kumar A, Kipps TJ et al (2021) Long-term follow-up of patients with relapsed or refractory Non-hodgkin Lymphoma Treated with Venetoclax in a phase I, first-in-human study. Clin Cancer Res 27(17):4690\u20134695. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4842","journal-title":"Clin Cancer Res"},{"issue":"22","key":"1471_CR9","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B et al (2017) Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 130(22):2401\u20132409. https:\/\/doi.org\/10.1182\/blood-2017-06-788786","journal-title":"Blood"},{"issue":"32","key":"1471_CR10","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ et al (2021) Phase I study of Venetoclax Plus Daratumumab and Dexamethasone, with or without Bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol 39(32):3602\u20133612. https:\/\/doi.org\/10.1200\/JCO.21.00443","journal-title":"J Clin Oncol"},{"issue":"19","key":"1471_CR11","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","volume":"5","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A et al (2021) Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Adv 5(19):3748\u20133759. https:\/\/doi.org\/10.1182\/bloodadvances.2020004146","journal-title":"Blood Adv"},{"key":"1471_CR12","doi-asserted-by":"crossref","unstructured":"Badawi M, Coppola S, Eckert D, Gopalakrishnan S, Engelhardt B, Doelger E et al (2023) Venetoclax in biomarker-selected multiple myeloma patients: impact of exposure on clinical efficacy and safety. Hematol Oncol 20230923 ed","DOI":"10.1002\/hon.3222"},{"issue":"7","key":"1471_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/15384047.2016.1192086","volume":"17","author":"KG Ponder","year":"2016","unstructured":"Ponder KG, Matulis SM, Hitosugi S, Gupta VA, Sharp C, Burrows F et al (2016) Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer Biol Ther 17(7):769\u2013777. https:\/\/doi.org\/10.1080\/15384047.2016.1192086","journal-title":"Cancer Biol Ther"},{"issue":"14","key":"1471_CR14","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-05-0676","volume":"65","author":"JZ Qin","year":"2005","unstructured":"Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V et al (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65(14):6282\u20136293. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0676","journal-title":"Cancer Res"},{"issue":"1","key":"1471_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(15)00464-7","journal-title":"Lancet Oncol"},{"issue":"5","key":"1471_CR16","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/leu.2015.350","volume":"30","author":"SM Matulis","year":"2016","unstructured":"Matulis SM, Gupta VA, Nooka AK, Hollen HV, Kaufman JL, Lonial S et al (2016) Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia 30(5):1086\u20131093. https:\/\/doi.org\/10.1038\/leu.2015.350","journal-title":"Leukemia"},{"key":"1471_CR17","doi-asserted-by":"crossref","unstructured":"Kaufman JL, Gasparetto C, Kovacsovics et al First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in patients with t(11;14) relapsed\/refractory multiple myeloma. Presented at: 2023 International Myeloma Society Annual Meeting; September 27\u201330, 2023; Athens, Greece. Abstract OA-29","DOI":"10.1016\/S2152-2650(23)01596-3"},{"issue":"3","key":"1471_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1124\/dmd.116.071613","volume":"45","author":"H Liu","year":"2017","unstructured":"Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J et al (2017) Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites. Drug Metab Dispos 45(3):294\u2013305. https:\/\/doi.org\/10.1124\/dmd.116.071613","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1471_CR19","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1208\/s12248-016-9927-9","volume":"18","author":"AK Jones","year":"2016","unstructured":"Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH (2016) Clinical predictors of Venetoclax Pharmacokinetics in Chronic lymphocytic leukemia and Non-hodgkin\u2019s Lymphoma patients: a Pooled Population Pharmacokinetic Analysis. AAPS J 18(5):1192\u20131202. https:\/\/doi.org\/10.1208\/s12248-016-9927-9","journal-title":"AAPS J"},{"issue":"8","key":"1471_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/CAD.0000000000000522","volume":"28","author":"AH Salem","year":"2017","unstructured":"Salem AH, Dunbar M, Agarwal SK (2017) Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Anticancer Drugs 28(8):911\u2013914. https:\/\/doi.org\/10.1097\/CAD.0000000000000522","journal-title":"Anticancer Drugs"},{"issue":"9","key":"1471_CR21","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/00498254.2017.1381779","volume":"48","author":"MS Chiney","year":"2018","unstructured":"Chiney MS, Menon RM, Bueno OF, Tong B, Salem AH (2018) Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin. Xenobiotica 48(9):904\u2013910. https:\/\/doi.org\/10.1080\/00498254.2017.1381779","journal-title":"Xenobiotica"},{"issue":"4","key":"1471_CR22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00228-017-2403-3","volume":"74","author":"KJ Freise","year":"2018","unstructured":"Freise KJ, Hu B, Salem AH (2018) Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. Eur J Clin Pharmacol 74(4):413\u2013421. https:\/\/doi.org\/10.1007\/s00228-017-2403-3","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1471_CR23","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s12325-018-0793-y","volume":"35","author":"SK Agarwal","year":"2018","unstructured":"Agarwal SK, Tong B, Bueno OF, Menon RM, Salem AH (2018) Effect of azithromycin on Venetoclax Pharmacokinetics in healthy volunteers: implications for Dosing Venetoclax with P-gp inhibitors. Adv Therapy 35(11):2015\u20132023. https:\/\/doi.org\/10.1007\/s12325-018-0793-y","journal-title":"Adv Therapy"},{"key":"1471_CR24","doi-asserted-by":"publisher","unstructured":"Noorani B, Menon RM, Chen X, Marsh KC, Huang W, Gupta S et al (2023 Oct) Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis. Br J Clin Pharmacol 19. https:\/\/doi.org\/10.1111\/bcp.15935","DOI":"10.1111\/bcp.15935"},{"issue":"2","key":"1471_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hon.2964","volume":"40","author":"D Brackman","year":"2022","unstructured":"Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD et al (2022) Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naive acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematol Oncol 40(2):269\u2013279. https:\/\/doi.org\/10.1002\/hon.2964","journal-title":"Hematol Oncol"},{"issue":"1","key":"1471_CR26","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s12325-021-01919-z","volume":"39","author":"D Samineni","year":"2022","unstructured":"Samineni D, Huang W, Gibiansky L, Ding H, Zhang R, Li C et al (2022) Population Pharmacokinetics and exposure-response analyses for Venetoclax in Combination with R-CHOP in Relapsed\/Refractory and previously untreated patients with diffuse large B cell lymphoma. Adv Therapy 39(1):598\u2013618. https:\/\/doi.org\/10.1007\/s12325-021-01919-z","journal-title":"Adv Therapy"},{"key":"1471_CR27","doi-asserted-by":"publisher","unstructured":"Badawi M, Coppola S, Eckert D, Gopalakrishnan S, Engelhardt B, Doelger E et al (2023) Venetoclax in biomarker-selected multiple myeloma patients: impact of exposure on clinical efficacy and safety. Hematological oncology. 23. https:\/\/doi.org\/10.1002\/hon.3222","DOI":"10.1002\/hon.3222"},{"issue":"8","key":"1471_CR28","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/jcph.2248","volume":"63","author":"JQX Gong","year":"2023","unstructured":"Gong JQX, Suleiman AA, Menon R, Deng R, Mensing S, Salem AH (2023) Pooled Population pharmacokinetic analyses of Venetoclax in patients across indications and healthy subjects from phase 1, 2, and 3 clinical trials. J Clin Pharmacol 63(8):950\u2013960. https:\/\/doi.org\/10.1002\/jcph.2248","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1471_CR29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40262-016-0453-9","volume":"56","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA et al (2017) Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Pharmacokinet 56(5):515\u2013523. https:\/\/doi.org\/10.1007\/s40262-016-0453-9","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1471_CR30","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/10428194.2017.1361024","volume":"59","author":"A Parikh","year":"2018","unstructured":"Parikh A, Gopalakrishnan S, Freise KJ, Verdugo ME, Menon RM, Mensing S et al (2018) Exposure-response evaluations of venetoclax efficacy and safety in patients with non-hodgkin lymphoma. Leuk Lymphoma 59(4):871\u2013879. https:\/\/doi.org\/10.1080\/10428194.2017.1361024","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1471_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hon.2373","volume":"35","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM et al (2017) Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematol Oncol 35(4):679\u2013684. https:\/\/doi.org\/10.1002\/hon.2373","journal-title":"Hematol Oncol"},{"issue":"4","key":"1471_CR32","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/hon.2646","volume":"37","author":"S Agarwal","year":"2019","unstructured":"Agarwal S, Gopalakrishnan S, Mensing S, Potluri J, Hayslip J, Kirschbrown W et al (2019) Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis. Hematol Oncol 37(4):464\u2013473. https:\/\/doi.org\/10.1002\/hon.2646","journal-title":"Hematol Oncol"},{"key":"1471_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.712","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Jones AK, Verdugo ME, Menon RM, Maciag PC, Salem AH (2017) Moving Beyond Maximum tolerated dose for targeted oncology drugs: Use of Clinical Utility Index to optimize Venetoclax Dosage in multiple myeloma patients. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.712","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1471_CR34","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/s1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21(12):1630\u20131642. https:\/\/doi.org\/10.1016\/s1470-2045(20)30525-8","journal-title":"Lancet Oncol"},{"issue":"5","key":"1471_CR35","doi-asserted-by":"publisher","first-page":"e0267979","DOI":"10.1371\/journal.pone.0267979","volume":"17","author":"P Daniele","year":"2022","unstructured":"Daniele P, Mamolo C, Cappelleri JC, Bell T, Neuhof A, Tremblay G et al (2022) Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. PLoS ONE 17(5):e0267979. https:\/\/doi.org\/10.1371\/journal.pone.0267979","journal-title":"PLoS ONE"},{"issue":"279","key":"1471_CR36","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK et al (2015) Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 7(279):279ra40. https:\/\/doi.org\/10.1126\/scitranslmed.aaa4642","journal-title":"Sci Transl Med"},{"issue":"11","key":"1471_CR37","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","volume":"67","author":"P Gomez-Bougie","year":"2007","unstructured":"Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, Trichet V, Robillard N, Philippe M et al (2007) Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67(11):5418\u20135424. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4322","journal-title":"Cancer Res"},{"issue":"0123","key":"1471_CR38","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/S2152-2650(23)01596-3","volume":"09","author":"J Kaufman","year":"2023","unstructured":"Kaufman J, Gasparetto C, Kovacsovics T, Mikala G, Masszi T, Rosi\u00f1ol L et al (2023) OA-29 first results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in patients with t(11;14) relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 09(0123):S18. https:\/\/doi.org\/10.1016\/S2152-2650(23)01596-3","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01471-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01471-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01471-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T09:11:51Z","timestamp":1733562711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01471-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1471"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01471-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"19 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies reported herein were conducted in accordance with the International Council for Harmonisation (ICH) guidelines, applicable regulations, and guidelines governing clinical study conduct and the ethical principles that have their origin in the Declaration of Helsinki. Approval was granted by institutional review boards and independent ethics committees at participating institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written consent prior to participation or study-related procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All individual participants signed informed consent regarding publishing their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MB, BE, ED, RMM, and AHS are employees of AbbVie and may hold AbbVie stock or options. RD is a paid consultant at Genentech\/Roche and may hold Genentech\/Roche stock or stock options. JLK receives research funding for clinical trials from AbbVie, Amgen, Allogene, Astra-Zeneca, BMS, Carsgen, GSK, Janssen, Novartis, Roche-Genentech, Takeda, Regeneron, Molecular Templates and participates on the advisory board\/provides consulting with no personal payments for AbbVie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium, Loxo Oncology, K36, Sanofi, ArcellX, and (with personal payment) Oncopeptides, Beigene, Antengene.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}